FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Co.), a leading global medical technology company, is pleased to be a Premium Partner at Pharmapack 2023 – the European hub for the pharmaceutical packaging and drug delivery device industry – which will take place on February 1-2, 2023 at Paris Expo, Porte de Versailles, in Paris,
FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Company) and Biocorp, a medical device and delivery systems manufacturer based in France, announced Tuesday that they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence
FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Co.) announced on Friday that it has completed its spinoff of Embecta Corp. (embecta) which holds BD’s former Diabetes Care business and is now one of the largest pure-play diabetes management companies in the world. “The completion of this spinoff is a significant achievement for both BD
FRANKLIN LAKES, N.J. – BD (Becton, Dickinson and Co.) has acquired Tissuemed, a privately held firm headquartered in Leeds, England that is an industry leader in developing self-adhesive surgical sealant films. The acquisition of Tissuemed expands BD’s global offerings for surgeons outside of the United States. Tissuemed’s lead product, Tissuepatch, is a proprietary sealant technology
MADRID, Spain — BD (Becton, Dickinson and Company) announced that it will build a €165 million ($200 million USD) high-tech manufacturing facility in city of Zaragoza, located in the Aragon region of Spain, that will create up to 600 jobs by 2030. BD plans to begin construction of the new plant in late 2021, and the
FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Company) has acquired GSL Solutions (GSL), a privately-held company that develops smart medication devices for the storage and tracking of controlled substances and patient specific medications that improve the security, efficiency and compliance of medication storage, as well as analytic capabilities to further improve inventory management, including
FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Company) a leading global medical technology company, and BioGX, a molecular diagnostics company, announced that the companies have submitted Emergency Use Authorization requests to the U.S. Food and Drug Administration (FDA) for new diagnostic tests that, if authorized, would increase the potential capacity to screen for COVID-19 (coronavirus)
